U.S. drugmaker Pfizer's new $11 billion share repurchase plan is deflating expectations that it will make a new bid for AstraZeneca.» Read More
The patient, who was taking Tecfidera, died earlier this month.
GlaxoSmithKline (GSK) reported third-quarter revenue lower than analysts forecast, as sales of blockbuster asthma drug Advair continued to fall.
An experimental trial Ebola vaccine could be in use in West Africa as early as January, the WHO said. NBC News reports.
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
Disruption in health care seems to have been a long time coming. Now the sector is innovating, fast.
Out of the headlines from the Ebola hearings, one big takeaway may have been lost: Every U.S. Ebola patient has been treated with at least one investigational product.
AbbVie is reconsidering its takeover of Shire, putting it on track to become the biggest deal to be torpedoed by a crackdown on tax inversions.
J&J reported strong earnings, boosted by sales of a new drug for hepatitis C that are expected to evaporate in coming months due to competition.
NIH Director Dr. Francis Collins has it a bit wrong when he blamed government budget cuts as the reason that we don’t have an Ebola vaccine already.
The first trial of an Ebola vaccine has started with the vaccination of three health care workers in Mali, researchers told NBC News.
The Ebola story has played out in the stock market recently largely on the backs of two companies: drugmakers Chimerix and Tekmira.
It's not unusual for big pharmaceutical companies to hold domains for major diseases on the Internet. But who would want to own Ebola.com?
Several drug companies are moving to test vaccines and drug treatments for Ebola, but their full effect might not be felt until the next outbreak.
Start-up Thync says it has raised $13 million to create a wearable brain device that promises to alter your state of mind, Re/code reports.
The Department of Veterans Affairs, has a new problem on its hands: a $1000 pill, The Fiscal Times reports.
GlaxoSmithKline, which was slapped with a record fine for corruption in China, said it was looking into allegations of corruption in UAE.
Chimerix's drug brincidofovir was approved for emergency use in treating Ebola patients, and is now being used on a case in Dallas.
Chimerix said its experimental Ebola drug has been provided for potential use in patients, sending its shares sharply higher in premarket trading.
The CDC director tells CNBC Ebola's spread in West Africa raises the possibility that the U.S. will see another patient with the disease.
The U.K.'s National Institute of Health and Care Excellence recommends doctors prescribe nalmefene to mild nightly drinkers.
Get the best of CNBC in your inbox